Jiachen Zhang,Ting Wang,Siang Wei,Shujia Chen,Juan Bi. GFPT2 pan-cancer analysis and its prognostic and tumor microenvironment associations. Oncol Transl Med, 2021, 7: 286-293.
GFPT2 pan-cancer analysis and its prognostic and tumor microenvironment associations
Received:June 10, 2021  Revised:December 31, 2021
View Full Text  View/Add Comment  Download reader
KeyWord:Glutamine fructose-6-phosphate transaminase 2 (GFPT2); pan-cancer, prognosis, immune, microenvironment
Author NameAffiliationDepartment
Jiachen Zhang The First Affiliated Hospital, Naval Medical University, Shanghai 200002, China Department of Pharmacy
Ting Wang The First Affiliated Hospital, Naval Medical University, Shanghai 200002, China Department of Pharmacy
Siang Wei The First Affiliated Hospital, Naval Medical University, Shanghai 200002, China Department of Pharmacy,
Shujia Chen The First Affiliated Hospital, Naval Medical University, Shanghai 200002, China Department of Pharmacy
Juan Bi The First Affiliated Hospital, Naval Medical University, Shanghai 200002, China Department of Pharmacy
Hits: 2838
Download times: 3308
Abstract:
      Objective Glutamine fructose-6-phosphate transaminase 2 (GFPT2) is involved in a wide range of biological functions in human cancer. However, few studies have comprehensively analyzed the correlation between GFPT2 and different cancer prognoses and tumor microenvironments (TMEs). Methods We evaluated the expression level and prognostic value of GFPT2 using updated public databases and multiple comprehensive bioinformatics analysis methods and explored the relationship between GFPT2 expression and immune infiltration, immune neoantigens, tumor mutational burden (TMB), and microsatellite instability in pan-cancer. Results GFPT2 was highly expressed in five cancers. GFPT2 expression correlates with the prognosis of several cancers from The Cancer Genome Atlas (TCGA) and is significantly associated with stromal and immune scores in pan-cancer. High GFPT2 expression in BLCA, BRCA, and CHOL was positively correlated with the infiltration of immune cells, such as B-cells, CD4+ T, CD8+ T cells, dendritic cells, neutrophils, and macrophages. Conclusion High GFPT2 expression may modify the outcomes of patients with BLCA, BRCA, or CHOL cancers by increasing immune cell infiltration. These findings may provide insights for further investigation into GFPT2 as a potential target in pan-cancer.
Close